Pharma News
01 Mar 2026 to 07 Mar 2026
Mar 7, 2026
Delhi's Drug Control Department confiscates insulin inventory valued at Rs 20.06 lakh.
The Delhi Drugs Control Department seized insulin stock valued at Rs 20.06 lakh during a special enforcement drive in a wholesale drug market. This initiative aims to ensure the availability of safe and effective medicines to the public, particularly focusing on insulin preparations.
Mar 7, 2026
With the patent expiration of semaglutide, a surge in weight-loss opportunities emerges. Pharmaceutical companies make significant investments while a legal dispute remains unresolved.
A Bengaluru investor, previously reliant on insulin for Type 2 diabetes, experienced significant weight loss and improved health after starting Mounjaro, developed by Eli Lilly. With the patent expiration of semaglutide on March 20, 2026, several Indian companies, including Sun Pharmaceutical and Zydus Lifesciences, are set to launch affordable generic versions, enhancing access to diabetes and obesity treatments.
Mar 7, 2026
Novo Nordisk and Hims & Hers Health Resolve Conflict, Set to Market Wegovy Collaboratively
Market analysts are surprised by the recent developments between Novo and Hims, who have been in a legal battle over Wegovy's active ingredient, Semaglutide. This ingredient is well-known for its weight loss benefits and effectiveness in treating diabetes.
Mar 7, 2026
Medivir to Present Progress in Phase 2 Trials for Major Cancer and Bone Disorder Initiatives
Medivir AB has announced advancements in its clinical programs for fostrox, targeting primary liver cancer, and MIV-711 for Osteogenesis Imperfecta. CEO Jens Lindberg will present at the DNB/Carnegie Healthcare Seminar 2026 on March 9. The company aims for both drugs to become first approved treatments in their fields, with a recent analyst rating of Buy for its stock (SE:MVIR).
Mar 7, 2026
Liberate Bio secures important CAR-M patents and plans to initiate its first clinical trials in 2026 - Indian Pharma Post
Liberate Bio has secured exclusive and non-exclusive licenses for key patents on chimeric antigen receptor (CAR) designs optimized for myeloid cells from Carisma Therapeutics and the University of Pennsylvania. This strengthens their clinical programs and complements their lipid nanoparticle (LNP) delivery platform. The company aims to advance its first in vivo CAR-M candidate toward clinical evaluation by late 2026.
Mar 7, 2026
Could This New Obesity Medication Rescue Novo Nordisk? - The Globe and Mail
Novo Nordisk is facing challenges in the weight loss market, losing ground to Eli Lilly's Zepbound. Despite disappointing results for its CagriSema drug, Novo Nordisk's mid-stage candidate UBT251 shows promise, achieving a 19.7% weight loss in 24 weeks. However, competition remains fierce, with Eli Lilly's retatrutide setting a high benchmark.
Mar 7, 2026
Novo and Hims resolve their dispute and will collaborate on the sale of obesity medications — Bloomberg - The Edge Malaysia
Novo Nordisk A/S is set to partner with Hims & Hers Health Inc to sell its weight-loss drugs, ending a legal dispute over Hims' copycat medications of Novo's Wegovy and Ozempic. This surprising collaboration comes as Hims' shares surged 40%, while Novo's stock rose 2.1%. The partnership reflects Novo's need to enhance market reach amid competition from Eli Lilly & Co.
Mar 7, 2026
Could This New Obesity Medication Rescue Novo Nordisk? - AOL.com
Novo Nordisk is facing challenges in the weight loss market, losing ground to Eli Lilly's Zepbound. Despite disappointing results for its CagriSema drug, Novo Nordisk's UBT251 shows promise, achieving a 19.7% weight loss in a mid-stage study. However, competition remains fierce, with Eli Lilly's retatrutide setting a high benchmark. Novo Nordisk aims to maintain its position in this growing market.
Mar 7, 2026
Novo and Hims Resolve Legal Dispute and Collaborate on Obesity Medications - Whalesbook
Novo Nordisk A/S and Hims & Hers Health Inc. have resolved their legal dispute to form a partnership for selling obesity drugs, including Wegovy and Ozempic. This collaboration aims to enhance patient access amid rising competition. Hims' shares surged 40% post-announcement, while Novo's ADRs also gained. The partnership reflects a strategic shift in the competitive obesity drug market.
Mar 7, 2026
Research Indicates Anti-Obesity Medication May Be Priced at Only $3 Monthly - The Morning News
Researchers suggest that semaglutide, the active ingredient in Novo Nordisk's weight-loss drugs Ozempic and Wegovy, could be manufactured for as low as $3 per month after patent expirations in several countries. This could lead to affordable access for millions suffering from obesity and diabetes, significantly impacting global health outcomes.
Mar 7, 2026
Eli Lilly's GLP-1 Medications Ignite Surge in Investments | Intellectia.AI
BofA reports that Novo Nordisk (NVO) plans to reduce GLP-1 list prices, but believes this will have minimal impact on the U.S. market. The firm suggests that Eli Lilly's (LLY) GLP-1 franchise will remain largely unaffected, maintaining a Buy rating on Eli Lilly. The update aims to lower patient costs but lacks significant changes in commercial reimbursement.
Mar 7, 2026
Medications Could Be Affordable If Not for Patents Driving Up Costs
Representative Rashida Tlaib's Medicines for the People Act proposes creating a National Institute for Biomedical Research and Development to develop drugs without patent monopolies, aiming to lower prices and reduce corruption in the pharmaceutical industry. The bill seeks to promote transparency and faster research sharing, although its chances of passing in Congress remain slim.
Mar 6, 2026
The impact of GLP-1 'miracle medications' for diabetes and obesity on lowering the likelihood of alcohol addiction.
A study from Washington University School of Medicine reveals that GLP-1 drugs, including semaglutide, liraglutide, and dulaglutide, significantly reduce the risk of severe addiction-related outcomes in Type 2 diabetes patients. Those on GLP-1 medications showed a 14-25% lower likelihood of developing substance use disorders compared to SGLT2 inhibitors. Researchers are exploring these drugs' potential in treating addiction directly.
Mar 6, 2026
Medivir to showcase at the DNB/Carnegie Healthcare Seminar - TradingView
Medivir AB will present at the DNB/Carnegie Healthcare Seminar on March 9, 2026, focusing on the phase 2 clinical development of MIV-711 for Osteogenesis Imperfecta and the ongoing phase 2 development of fostrox for primary liver cancer. Both drug candidates have significant potential as first approved treatments in their respective areas.
Mar 6, 2026
Leading Pharmaceutical Firms Accelerate Development of Weight-Loss Medications Amid Market Changes
The weight-loss medication industry is rapidly evolving, with companies like Eli Lilly, Novo Nordisk, and Pfizer developing oral alternatives to injectable treatments. Eli Lilly's orforglipron shows promising results, while Novo Nordisk leads with a GLP-1 pill. Other firms, including Merck, AstraZeneca, and Structure Therapeutics, are also advancing oral GLP-1 agonists, prompting analysts to reassess market predictions.
Mar 6, 2026
Study Indicates GLP-1 Medications Could Increase Osteoporosis and Gout Risk - Health
New research presented at the American Academy of Orthopaedic Surgeons suggests prolonged use of GLP-1 medications, including Ozempic and Wegovy, may be associated with a higher risk of osteoporosis and gout. The study tracked nearly 150,000 individuals, revealing a 29% increased risk of osteoporosis and a 12% increased risk of gout among GLP-1 users. However, the findings do not establish causation.
Mar 6, 2026
Key Insights on the Potential of GLP-1 Medications in Combating Addiction - Vincennes Sun-Commercial
A new study suggests that GLP-1 drugs, such as Ozempic and Mounjaro, may help prevent substance use disorders among diabetes patients. Analyzing over 600,000 Veterans Affairs records, researchers found these medications reduced addiction risks to alcohol, nicotine, and opioids. They also linked GLP-1s to lower hospitalization and overdose rates in those already addicted, indicating potential for new addiction treatments.
Mar 6, 2026
Research Indicates Imitations of Ozempic May Be Priced at $3 - TradingView
Novo Nordisk (NVO) may soon face competition for its GLP-1 drugs, Ozempic and Wegovy, as a study suggests generic versions of semaglutide could be manufactured for under $3 per month. The research estimates injectable generics could cost $28 to $140 annually, while oral versions may range from $186 to $380, coinciding with expiring patents in several countries.
Mar 6, 2026
Research Indicates That After Patent Expiration, the Obesity Medication Semaglutide May Be Priced at $3 Per Month
A new study reveals that semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, could be manufactured for as low as $3 per month after patent expirations in several countries. This could enhance access to treatment for Type 2 diabetes and obesity, particularly in low- and middle-income nations, where current branded versions cost around $200 monthly.
Mar 6, 2026
Union Budget 2026-27 and Availability of Medications - Live Law
The Union Budget 2026-27 announced the removal of basic customs duty on 17 cancer medicines and extended import duty exemptions for seven additional rare diseases. This marks the third consecutive budget to provide such exemptions, aiming to enhance access to essential medications.
Mar 6, 2026
Novo Nordisk Takes on Compounded Alternatives Amidst the GLP-1 Surge
Novo Nordisk has filed a federal lawsuit against Hims & Hers, alleging patent infringement related to compounded semaglutide products, including Ozempic® and Wegovy®. The case highlights the intersection of telehealth, compounding practices, and pharmaceutical patent rights, as the FDA warns against marketing non-FDA-approved GLP-1 drugs. Hims has since ceased offering compounded semaglutide pills amid increased regulatory scrutiny.
Mar 6, 2026
Study reveals weight-loss injection could cost as little as $3 per month | Global health | The Guardian
New analysis suggests that semaglutide, marketed as Wegovy for obesity and Ozempic for diabetes, could be produced for just $3 a month, potentially increasing access in low-income countries as patents expire. Researchers emphasize the need for coordinated policies to address obesity's structural drivers, despite the promising cost reduction.
Mar 6, 2026
Regulatory Holdups Drive Underground Market for Cough Syrups and Narcotics
Authorities in India have uncovered a significant underground trade involving the diversion of prescription drugs, particularly codeine-based cough syrups and narcotic capsules. Recent police raids in Uttar Pradesh, Bihar, Punjab, and Gujarat have led to multiple arrests, highlighting the growing issue of drug smuggling amid regulatory delays.
Mar 6, 2026
Weekly Summary: Moderna reaches historic settlement regarding COVID vaccine patents
Moderna has reached a $2.25 billion settlement with Arbutus Biopharma and Roivant's Genevant over COVID-19 vaccine patent claims related to Spikevax. The deal includes a $950 million upfront payment and resolves disputes over lipid nanoparticle technology. This settlement is poised to be the largest patent settlement in the pharmaceutical industry.
Mar 6, 2026
Study: Wegovy and Ozempic injections might cost as low as $3 monthly - STAT
A new analysis suggests that generic versions of Novo Nordisk’s Wegovy and Ozempic, containing the active ingredient semaglutide, could be produced for about $3 per person per month. Patents for semaglutide are set to expire soon in several countries, including India and China, potentially increasing access to these medications in low- and middle-income regions.
Mar 6, 2026
D&D Pharmatech and FirstBio Obtain European Patent for Medication Targeting Brain Disorders
D&D Pharmatech and FirstBio Therapeutics have secured a European patent for their neurodegenerative disease drug, NLY02. This follows prior approval in the U.S., completing their intellectual property protection in key markets. NLY02, an oral compound targeting RIPK2 to protect brain neurons, is in preclinical development for conditions like Parkinson's and Alzheimer's. The companies plan to enhance global commercialization efforts.
Mar 6, 2026
Indian Pharmaceutical Industry's 'Sema' Surge: More Than 50 Semaglutide Brands Prepare to Launch Following Ozempic Patent Expiration
As the patent for semaglutide, marketed as Ozempic and Wegovy by Novo Nordisk, expires in India, over 50 Indian pharmaceutical companies are preparing to launch their own versions, many starting with the prefix "Sema." This influx is expected to halve prices, improving access to GLP-1 therapies for diabetes and obesity treatment. Companies like Alkem, Mankind, and Sun Pharma are among those entering the market.
Mar 6, 2026
Celltrion Aims to Address Major Patent Expirations with New Biosimilar Products - 팜이데일리
Celltrion is advancing its biosimilar development, targeting blockbuster drugs as patents expire. The company aims to expand its portfolio from 11 to 18 products by 2030, including biosimilars for Ocrevus (CT-P53), Cosentyx (CT-P55), and Keytruda (CT-P51). With a focus on subcutaneous formulations, Celltrion plans to leverage its capabilities to capture a growing market projected to reach 274 trillion won.
Mar 6, 2026
Key Insights on the Potential of GLP-1 Medications in Combating Addiction - WUSF
A recent study reveals that GLP-1 medications, commonly prescribed for diabetes and obesity, may also be effective in combating various substance use disorders. This finding highlights the potential of these drugs beyond their traditional applications.
Mar 6, 2026
Alan Healy: Ireland fully commits to weight-loss medications
Recent export data highlights Ireland's reliance on the tech and pharma sectors, particularly due to the rising demand for weight-loss drugs. This trend reinforces the dominance of blockbuster drugs, echoing the historical success of Pfizer in producing global brands like Viagra and Lipitor in Cork.
Mar 6, 2026
Phil Low, a globally recognized pioneer in drug discovery from Purdue University, has passed away at the age of 78 - Journal & Courier.
Phil Low, a pioneering researcher in drug discovery at Purdue University, has passed away at 78. He was instrumental in developing cancer therapies like Pluvicto and Cytalux and founded seven companies, including Endocyte, which was sold to Novartis. Low's legacy includes a $20 million donation to establish the Low Institute for Therapeutics at Purdue.
Mar 5, 2026
Marquis Who's Who Recognizes Dr. Elham Nejati for Her Knowledge in the Pharmaceutical Industry
Elham Nejati, PhD, has been honored by Marquis Who's Who for her expertise in the pharmaceutical sector, particularly in drug delivery and formulation at Gilead Sciences Inc. She holds three patents for long-acting injectables and two for oral solid dosage forms. Dr. Nejati aims to further her career by establishing a drug delivery consulting firm.
Mar 5, 2026
Wellgistics Health Chooses Leading Five Blockchain Platforms for Launching Patent-Protected Initiatives - IndyStar
Wellgistics Health, Inc. (NASDAQ:WGRX) has selected Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum/Besu, and Corda (R3) as the blockchain platforms for its PharmacyChain™ project. This initiative aims to enhance pharmaceutical drug tracking and comply with the Drug Supply Chain Security Act. The U.S. prescription drug market is projected to grow from $634 billion to $883 billion by 2030.
Mar 5, 2026
Moderna agrees to a settlement of up to $2.25 billion regarding a patent dispute over drug delivery technology.
Moderna has settled a patent infringement lawsuit with Genevant and Arbutus for up to $2.25 billion, resolving claims that it used their lipid nanoparticle technology in its Covid-19 vaccine, Spikevax. The settlement includes a $950 million upfront payment and a potential $1.3 billion contingent on court decisions. This resolution allows Moderna to focus on future growth amid challenges in its vaccine portfolio.
Mar 5, 2026
Zacks Industry Analysis Spotlights Teva Pharmaceuticals, Sandoz, and Dr. Reddy's
Teva Pharmaceuticals, Sandoz, and Dr. Reddy’s Laboratories are highlighted as key players in the generic drug market, facing challenges from competition and price declines. Teva's U.S. generics business rose 2% in 2025, while Sandoz reported a 5% increase in net sales. Dr. Reddy's focuses on complex generics, with 73 FDA filings pending. The industry remains under pressure but shows potential for growth.
Mar 5, 2026
Lilly's Study on Tirzepatide During Fasting Aims to Address Safety Concerns Related to Obesity Treatment
Eli Lilly and Company (LLY) has updated its clinical study on tirzepatide, also known as LY3298176, focusing on the effects of fasting and temporary withholding of the drug on gastric contents. The Phase 1 study aims to clarify safety concerns related to sedation procedures for users of GLP-1 drugs. Enrollment is ongoing, with recent protocol confirmations.
Mar 5, 2026
Moderna agrees to a settlement of up to $2.25 billion regarding a patent dispute over drug delivery technology - Yahoo Finance
Moderna has agreed to pay up to $2.25 billion to settle a patent infringement lawsuit with Genevant and Arbutus over the use of their lipid nanoparticle technology in its Covid-19 vaccine, Spikevax. The settlement includes a $950 million upfront payment and potential additional charges. This resolution allows Moderna to focus on future growth amid ongoing challenges in its vaccine portfolio.
Mar 5, 2026
Lilly introduces a platform for employers to expand access to weight-loss medications | WTVB
Mar 5, 2026
The potential of GLP-1 drugs in combating addiction - 1News
A new study suggests that GLP-1 drugs, including Ozempic and Mounjaro, may help prevent substance use disorders among diabetes patients. Analyzing over 600,000 Veterans Affairs records, researchers found those on GLP-1 medications had lower addiction risks and reduced hospitalizations and overdose rates. The findings indicate potential for these drugs in addiction treatment, though further clinical trials are needed.
Mar 5, 2026
Q4 Earnings Surprises: Bristol-Myers Squibb (NYSE:BMY) and Others...
In Q4, Bristol-Myers Squibb (BMY) reported revenues of $12.5 billion, exceeding expectations by 4.8%, while Eli Lilly (LLY) achieved a remarkable 42.6% revenue growth to $19.29 billion. Corcept (CORT) faced disappointment with revenues of $202.1 million, missing estimates by 18.5%. Supernus Pharmaceuticals (SUPN) and Zoetis (ZTS) also reported mixed results, with varying impacts on their stock prices.
Mar 5, 2026
GLP-1 diabetes medications associated with lower likelihood of addiction and fatalities related to substances.
A large US study published in The BMJ suggests that glucagon-like peptide-1 (GLP-1) receptor agonists, typically used for type 2 diabetes and obesity, may reduce the risk of various substance use disorders (SUDs) and improve outcomes for those with pre-existing SUDs. The findings indicate a 14% overall reduced risk of SUDs among veterans without a history of SUDs.
Mar 5, 2026
Lilly introduces a platform for employers to enhance access to weight-loss medication | WKZO
Mar 5, 2026
Can obesity medications help with addiction? A large study suggests potential benefits - Nature
A study published in The BMJ suggests that GLP-1 medications, primarily used for obesity and type 2 diabetes, may reduce the risk of addiction and lower mortality from substance-use disorders by 50%. Analyzing data from over 600,000 veterans, researchers found significant reductions in addiction risk for various substances, including alcohol and opioids. Further clinical trials are needed to confirm these findings.
Mar 5, 2026
Novo Nordisk Invests $502 Million to Expand Tablet Manufacturing Plant in Ireland
Novo Nordisk is investing $502 million to expand its tablet manufacturing facility in Athlone, Ireland, enhancing production of oral GLP-1 treatments, including the obesity drug Wegovy (semaglutide). Concurrently, Eli Lilly is investing $1.2 billion in Puerto Rico and building a $3 billion facility in the Netherlands to support its oral GLP-1 drug, orforglipron.
Mar 5, 2026
US FDA issues another warning to Novo regarding deceptive medication marketing.
The FDA has issued a warning to Novo Nordisk regarding misleading advertising for its diabetes drug, Ozempic. This marks the second warning in less than a month, as the FDA intensifies scrutiny on drug promotions following President Trump's directive for stricter oversight. The FDA's letter highlighted misrepresentations of Ozempic's approved uses and its comparison to other GLP-1 medications.
Mar 5, 2026
Q4 Highlights for Generic Pharmaceutical Stocks: Amphastar Pharmaceuticals (NASDAQ: AMPH)
In Q4, generic pharmaceutical stocks showed mixed results, with Amphastar Pharmaceuticals (AMPH) reporting disappointing revenues of $183.1 million, down 1.8%, and a 23.7% stock decline. In contrast, ANI Pharmaceuticals (ANIP) excelled with a 29.6% revenue increase to $247.1 million. Amneal Pharmaceuticals (AMRX) and Viatris (VTRS) also reported growth but faced stock declines.
Mar 4, 2026
Three Generic Pharmaceutical Stocks to Monitor Amid Industry Challenges - Yahoo Finance
Recent launches of biosimilars for J&J’s Stelara, Amgen’s Prolia/Xgeva, and Regeneron’s Eylea highlight the competitive landscape in the generic drug market. Companies like Teva Pharmaceuticals (TEVA), Sandoz (SDZNY), and Dr. Reddy’s Laboratories (RDY) are well-positioned to navigate challenges, with Teva's stock rising 103% and Sandoz's 90% over the past year.
Mar 4, 2026
US FDA issues another warning to Novo regarding deceptive medication marketing | WKZO
The FDA has warned Novo Nordisk about misleading advertising for its diabetes drug, Ozempic, marking the second warning in a month. The agency stated the ad misrepresented Ozempic’s uses and suggested it was superior to other GLP-1 medications. Novo Nordisk must respond within 15 days to address these concerns.
Mar 4, 2026
Moderna agrees to pay Roivant as much as $2.25 billion to resolve a patent dispute related to mRNA vaccines.
Moderna has agreed to pay Roivant up to $2.25 billion to settle patent infringement claims related to its Covid-19 vaccine. The settlement, one of the largest in history, includes an initial $950 million and an additional $1.3 billion contingent on legal appeals. The dispute focused on the lipid nanoparticles used to deliver mRNA, originally developed by Tekmira, now Arbutus.
Mar 4, 2026
NPPA sets retail prices for 20 newly approved medications, according to DrugsControl Media Services.
The National Pharmaceutical Pricing Authority (NPPA) has set the retail prices for 20 new drugs, including hypertensive medicines and ophthalmic solutions, in accordance with the Drugs Prices Control Order (DPCO), 2013. This decision was made during a recent meeting held in New Delhi.
Mar 4, 2026
Key insights on the potential of GLP-1 drugs in combating addiction - The Washington Post
A new study suggests that GLP-1 drugs, such as Ozempic and Mounjaro, may help prevent substance use disorders among diabetes patients. Analyzing over 600,000 Veterans Affairs records, researchers found those on GLP-1s had lower addiction risks and reduced hospitalizations and overdose rates. While promising, further randomized trials are needed to confirm these findings.
Mar 4, 2026
US FDA issues second warning to Novo regarding deceptive medication marketing - AOL.com
The U.S. FDA has ordered Novo Nordisk to cease a consumer advertisement for its diabetes drug Ozempic, citing false and misleading claims. This marks the second warning in a month, following a similar notice regarding a TV ad for Wegovy, Novo's weight-loss medication. Novo Nordisk has not yet commented on the situation.
Mar 4, 2026
Aspen Pharmaceuticals aims for Mounjaro's approval in sub-Saharan Africa within this year.
Aspen Pharmacare plans to secure sub-Saharan African approval for Eli Lilly's weight-loss drug Mounjaro this year, capitalizing on rising demand for obesity treatments. Mounjaro, launched in South Africa in late 2024, has significantly increased the GLP-1 market, with sales expected to exceed 1.3 billion rand. Aspen aims to be a key partner for global drugmakers in the region.
Mar 4, 2026
Aspen Pharmaceuticals aims for Mounjaro's approval in sub-Saharan Africa within this year - WHBL
Aspen Pharmacare plans to secure sub-Saharan African approval for Eli Lilly's weight-loss drug Mounjaro this year, capitalizing on rising demand for obesity treatments. Mounjaro, launched in South Africa in late 2024, has significantly increased the GLP-1 market, with sales expected to exceed 1.3 billion rand. Aspen aims to become a key partner for global drugmakers in the region.
Mar 4, 2026
Keytruda Retains Top Selling Status Amid Rising Popularity of GLP-1 Medications - BioSpace
Merck's Keytruda remains the top-selling drug in 2025, generating nearly $32 billion, despite competition from Eli Lilly's Mounjaro and Novo Nordisk's Ozempic, which collectively surpassed Keytruda's sales. Lilly's Mounjaro earned $22.965 billion, while Novo's semaglutide franchise brought in $36.19 billion. Sanofi/Regeneron's Dupixent and AbbVie's Skyrizi also showed strong sales growth in the immunology sector.
Mar 4, 2026
FDA Issues Second Warning to Novo Over Deceptive Ozempic Promotions - NTD News
The FDA has warned Novo Nordisk over misleading advertising for its diabetes drug, Ozempic, claiming it misrepresented the drug's benefits and eligibility criteria. This marks the second warning in less than a month, following a similar issue with its weight-loss drug, Wegovy. Novo Nordisk is required to respond to the FDA's concerns within 15 days.
Mar 4, 2026
U.S. Supreme Court to Consider Case on Induced Infringement Related to 'Generic Vascepa®'
The U.S. Supreme Court will hear Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc. on April 29, 2026, regarding alleged induced infringement of Amarin's drug Vascepa®. The case questions if Hikma's marketing of its generic version, despite a "skinny label," constitutes active inducement to infringe on patented uses. The outcome may significantly impact generic drug competition and patent law.
Mar 4, 2026
Top Selections: Rising Oncology Needs and AI Propel Healthcare Growth Forecast - BNN Bloomberg
Brian Tanquilut, an equity analyst at Jefferies, highlighted growth opportunities in healthcare services, particularly in oncology treatments and diagnostic imaging. He recommended BrightSpring Health Services, McKesson Corp., and RadNet, citing rising demand for cancer care and the impact of AI in diagnostics. Patent expirations for drugs like Keytruda may also enhance margins for McKesson.
Mar 4, 2026
Moderna resolves patent disputes related to its COVID vaccine for $950 million | WBUR News
Moderna has settled patent lawsuits over its COVID-19 vaccine for $950 million, with an additional $1.3 billion contingent on a federal appeal outcome. The settlement resolves all worldwide litigation, allowing Moderna to avoid royalties. CEO Stéphane Bancel emphasized the importance of focusing on the company's future. The lawsuits were initiated by Arbutus Biopharma and Genevant Sciences GmbH.
Mar 4, 2026
What is the effect of drug monopolies on individuals living with HIV? - Agencia Presentes
A recent agreement between Argentina and the U.S. threatens to repeal Argentina's Patentability Guidelines, which have historically protected access to essential medicines, particularly for HIV. Activists warn this could exacerbate healthcare access issues across Latin America, especially as Gilead Sciences excludes many countries from pricing agreements for Lenacapavir, a key HIV prevention drug.
Mar 4, 2026
DCGI Suggests Limited Licenses for PMBJKs in Rural Regions - Drugscontrol
The Drugs Controller General of India (DCGI) has proposed granting restricted licenses for Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) in rural and tribal areas to enhance access to affordable medicines. This initiative aims to address healthcare disparities in underserved regions, as outlined in a recent circular to State and Union Territory licensing authorities.
Mar 4, 2026
Navigating the Complexities of Double Patenting Across Multiple Jurisdictions - Mondaq
A recent analysis by Michael Huang from Spruson & Ferguson highlights the complexities of double patenting laws in China, Hong Kong, and Southeast Asia. In China, multiple patents for non-identical claims are permitted, while Hong Kong and SEA countries also limit double patenting to "same invention" scenarios. The article emphasizes the need for careful claim management across jurisdictions.
Mar 4, 2026
DCGI Issues Immediate Warning Regarding Theft of Essential Insulin Medication: Lantus® SoloStar® Batch
The Drugs Controller General of India (DCGI) has issued an urgent alert regarding the theft of a critical batch of Lantus® SoloStar® (Insulin Glargine Injection IP, r-DNA origin, 100 IU). The alert aims to ensure public safety and prevent misuse of the stolen medication.
Mar 4, 2026
Moderna reaches a settlement while the FDA issues warning letters - Stat News
Moderna has agreed to pay Roivant up to $2.25 billion to settle patent infringement claims related to its Covid-19 vaccine, avoiding a jury trial. Roivant will receive $950 million upfront and potentially $1.3 billion more. Meanwhile, Virginia lawmakers are proposing a prescription drug affordability board to set price limits based on Medicare benchmarks, aiming to enhance cost containment efforts.
Mar 4, 2026
CBI charges three individuals and initiates investigation into unlawful drug production operation in Puducherry.
The CBI has initiated an investigation into an illegal drug manufacturing racket in Puducherry, booking three individuals linked to at least two companies. This action follows approval from the Union Home Ministry, as the agency seeks to address the growing concerns over illicit pharmaceutical activities in the region.
Mar 3, 2026
Alvotech's Investment in Biosimilars: The Growing Attention from Wall Street
Alvotech is emerging as a significant player in the biosimilar market, focusing on developing cost-effective alternatives to expensive biologic drugs in the US. With a robust pipeline and partnerships with major distributors, Alvotech aims to lower drug prices and challenge Big Pharma. Analysts highlight both the potential for market disruption and the risks associated with regulatory approvals and competition.
Mar 3, 2026
The expiration of the Semaglutide patent creates a $6 billion chance for Indian generic pharmaceutical companies.
India's leading generic companies, including Sun Pharma and Dr Reddy's Laboratories, are poised to launch affordable versions of semaglutide, a diabetes and weight management drug by Novo Nordisk, following its patent expiration. Prices are expected to drop by 30-50%, potentially reaching 70-75%. The Indian market alone could generate over $250 million initially, with significant opportunities in Canada and Brazil as well.
Mar 3, 2026
EirGen Pharma and Meissner Bolte uphold fundamental patent for renal medication.
DSM Nutritional Products has opposed EirGen Pharma's patent EP 2 968 172, which protects formulations of calcifediol used in Rayaldee, a treatment for secondary hyperparathyroidism. The EPO Boards of Appeal upheld the patent's novelty, rejecting DSM's requests. The dispute continues as DSM appeals against two other related patents. EirGen Pharma is represented by Meissner Bolte.
Mar 3, 2026
AnaptysBio (NASDAQ: ANAB) announces a planned split that will separate its royalties from its development pipeline - Stock Titan
AnaptysBio, Inc. announced plans to separate into two independent companies by mid-2026. One will focus on immunology therapeutics, including rosnilimab for rheumatoid arthritis, while the other will manage collaborations, including royalties from GSK's Jemperli (dostarlimab) and Vanda's imsidolimab. The separation aims to enhance shareholder value and streamline operations.
Mar 3, 2026
Moderna reaches agreement in Covid vaccine patent lawsuit for as much as $2.25 billion - STAT
Moderna has reached a $2.25 billion settlement with Roivant over patent infringement claims related to its Covid-19 vaccine. The agreement includes an initial payment of $950 million, with an additional $1.3 billion contingent on the outcome of Moderna's appeal to offload liability to the federal government, potentially marking one of the largest patent settlements ever.
Mar 3, 2026
Challenges in Defining and Claiming Approved Biologics for Patent Term Extension
The article discusses the complexities of Patent Term Extension (PTE) for biologic drugs, highlighting challenges in defining the "active ingredient." It uses YESCARTA® (axicabtagene ciloleucel) as a case study, illustrating the difficulties in PTE applications. The article emphasizes the need for a strategic approach in patent portfolio development to maximize PTE benefits amid evolving legal frameworks.
Mar 3, 2026
BMY Sees 11.4% Increase Over the Past Month: Is It Time to Buy, Sell, or Hold? - The Globe and Mail
Bristol Myers Squibb (BMY) shares have surged 11.4% over the past month, outperforming the industry and S&P 500. Strong fourth-quarter results, driven by its growth portfolio including Opdivo, Reblozyl, and Camzyos, have boosted investor confidence. However, the legacy portfolio faces challenges from generic competition. BMY's pipeline and strategic acquisitions may enhance future growth, while 2026 revenue is projected to decline.
Mar 3, 2026
India Faces Drug Diversion Crisis: Lack of Track-and-Trace System and Excessive...
A recent surge in the seizure of codeine-based cough syrups and narcotic tablets in India highlights a drug diversion epidemic. Experts attribute this crisis to the lack of a track-and-trace system, excessive codeine allotments, and regulatory apathy, raising concerns over the misuse of these pharmaceuticals.
Mar 3, 2026
J&J's successful Spravato is paving the way for addressing the risks associated with psychedelics.
Johnson & Johnson's depression drug, Spravato, achieved blockbuster status in 2024, with sales reaching nearly $1.7 billion, a 57% increase from the previous year. Approved in 2019, Spravato, based on esketamine, offers a fast-acting alternative for treatment-resistant depression. Despite its success, clinicians remain cautious due to ketamine's history and potential for abuse, emphasizing the need for careful prescribing practices.
Mar 3, 2026
Novo Nordisk plans to reduce the US list price of Wegovy by 50% in 2027 | Jefferson City News Tribune
Novo Nordisk announced a significant price reduction for its diabetes and weight-loss drugs, Ozempic and Wegovy, cutting list prices by up to 50% to $675 per month starting January 1, 2027. This move aligns with new Medicare pricing and aims to benefit insured consumers. The cuts also apply to Rybelsus, amid increasing competition in the GLP-1 drug market.
Mar 3, 2026
Hims' growth might not align with the high-stakes GLP-1 market - Brand Equity
Hims & Hers Health is facing investor impatience as it seeks to diversify from its reliance on compounded GLP-1 sales. The company recently faced regulatory scrutiny for planning a $49 version of Novo Nordisk's Wegovy, prompting a reversal after the FDA referred it to the Department of Justice over potential ingredient restrictions.
Mar 3, 2026
Sanofi's Wayrilz Receives Orphan Drug Designation for IgG4-Related Disease in Japan - TradingView
Sanofi (SNY) has received orphan drug designation from Japan’s MHLW for Waylirz (rilzabrutinib) to treat IgG4-related disease (IgG4-RD). This designation offers regulatory and financial advantages, aiding its clinical development. Waylirz, a BTK inhibitor, is also approved for immune thrombocytopenia and faces competition from Amgen’s Uplizna and others in various indications.
Mar 3, 2026
GLP-1 Weight Loss Medications: Strategies for Patients Facing Insurance Coverage Loss
Blue Cross Blue Shield of Massachusetts and Point32Health have stopped covering GLP-1 drugs for weight loss, affecting over 40,000 patients, including those using Zepbound. Patients now face costs up to $500 monthly, leading to concerns about regaining weight and worsening health. Insurers cite unsustainable costs from pharmaceutical companies Eli Lilly and Novo Nordisk, which dominate the GLP-1 market.
Mar 3, 2026
Aspen's profits take a hit from restructuring, yet Mounjaro sales offer a glimmer of optimism - Bizcommunity
Aspen Pharmacare reported a 21% decline in normalized earnings, impacted by R695m restructuring costs in its South African and French sterile manufacturing facilities. Despite this, strong demand for Eli Lilly's weight-loss drug Mounjaro, which Aspen markets in South Africa, supported revenue growth in its Commercial Pharmaceuticals segment. Overall group revenue decreased by 4% to R21.1bn.
Mar 3, 2026
Zydus's Initial GLP-1 Strategy: A Missed Chance or Wise Financial Oversight?
Zydus Lifesciences, once a pioneer with its oral GLP-1 agonist ZYOG1, shelved its development in 2010 due to high costs and regulatory challenges. Today, the booming GLP-1 market, led by Novo Nordisk and Eli Lilly, highlights a stark contrast in financial viability. Zydus faces mixed analyst ratings and must adapt to the evolving landscape to succeed in the obesity drug sector.
Mar 3, 2026
Efforts to ensure the affordability of the HIV 'miracle medication' for the Indian population - Scroll.in
Eldred Tellis, founder of the Sankalp Rehabilitation Foundation, advocates for the accessibility of Lenacapavir, a promising HIV prevention drug by Gilead Sciences. With a 96% reduction in HIV incidence, it could significantly benefit high-risk groups in India. However, Gilead's patent applications may make it unaffordable, prompting Tellis to file oppositions to ensure broader access.
Mar 3, 2026
Alteogen on the Verge of Success in the US: Can It Take the Lead in the SC Formulation Competition?
Alteogen has secured significant technology transfer agreements with AstraZeneca and GSK's Tesaro, totaling approximately 2.6 trillion won, amid a favorable UK patent ruling against Halozyme in their dispute with Merck. The outcome of an upcoming U.S. patent trial could further enhance Alteogen's position in the competitive subcutaneous formulation market, particularly with its hyaluronidase technology, ALT-B4.
Mar 2, 2026
Xeris Biopharma plans to invest in research and development as well as increase its workforce after a rise in medication sales.
Three hospitals in Chicago have been recognized among the top 250 hospitals globally in Newsweek's eighth annual ranking. This acknowledgment highlights the hospitals' excellence in healthcare services on an international scale.
Mar 2, 2026
Roundhill Investments Introduces Weight Loss ETF to Invest in Popular Medications Such as Ozempic
Wall Street analysts have downgraded Novo Nordisk (NVO) stock, with Morgan Stanley shifting from Underweight to Equal Weight and lowering its price target from $42 to $40. Goldman Sachs also downgraded the stock from Buy to Neutral, reducing its target from $63 to $41, citing disappointing REDEFINE-4 trial results impacting estimates for CagriSema.
Mar 2, 2026
Cancer treatment cost surge: Keytruda priced at the equivalent of eight years of average income in India - India Today
A study by Tata Memorial Centre reveals that a six-month course of Keytruda (pembrolizumab) costs 7,994% of the average monthly income in India, highlighting the unaffordability of modern cancer therapies. The research calls for structural reforms in drug pricing to improve access, as current costs push families into financial distress.
Mar 2, 2026
Merck and Pfizer's Combination Therapy 'Redefines Treatment Standards' for Bladder Cancer - BioSpace
Merck and Pfizer's combination of Keytruda and Padcev has shown promising results in a late-stage study for muscle-invasive bladder cancer, significantly improving survival and treatment response. The therapy reduced disease progression risk by 47% and overall mortality by 35% compared to standard care. Analysts suggest this could redefine treatment standards in the field.
Mar 2, 2026
The Importance of Novo Nordisk's Expansion in Ireland for Competing with Eli Lilly - CNBC
Novo Nordisk is investing €432 million ($506 million) in an Irish facility to boost production of its newly launched Wegovy pill, following a strong U.S. debut. This expansion aims to meet global demand amid competition from Eli Lilly. Despite past supply issues, Novo asserts it can meet U.S. demand and is seeking approval for Wegovy in Europe by year-end.
Mar 2, 2026
Health Risks Uncovered in Multi-State Distribution of Counterfeit RituxiRel and Alburel Injections
The FDA Pune Division has identified counterfeit batches of "RituxiRel," a fake version of Rituximab, highlighting significant vulnerabilities in India's pharmaceutical supply chain. This discovery raises concerns about drug safety and regulatory oversight in the country.
Mar 2, 2026
Pfizer Shares: Should You Invest, Divest, or Maintain Your Position Following an 11% Increase in 2026? - TradingView
Pfizer's (PFE) stock has risen 11% in 2026, recovering from previous declines due to lower COVID product sales. Despite strong oncology performance and strategic acquisitions like Seagen, its 2026 revenue guidance fell short, projecting $59.5-$62.5 billion. Analysts express caution due to patent expirations and Medicare headwinds, suggesting short-term investors may want to avoid the stock.
Mar 2, 2026
The $300 Billion Challenge Facing Major Pharmaceutical Companies... And Their $1.2 Trillion Answer | Stansberry Research
Health care stocks are experiencing a resurgence, but the pharmaceutical industry faces a significant challenge with over $300 billion in drug revenues set to lose patent protection by 2030. This has sparked a potential M&A frenzy, as Big Pharma, with $1.2 trillion in cash, seeks innovative biotech firms for new drug candidates. Investors should watch for opportunities in this evolving landscape.
Mar 2, 2026
Uncovered: The Unique Strategies ICBs are Implementing for Mounjaro Prescriptions - The Pharmacist
In June 2025, GPs began prescribing tirzepatide (Mounjaro) for obesity, previously approved for diabetes. Despite its potential as a "game changer," strict eligibility criteria and regional variations limit access, with many patients unable to receive treatment. NHS spending on tirzepatide has surged, but disparities in access persist, prompting concerns over equitable healthcare.
Mar 2, 2026
MDC suggests that Intas Pharma's patented antipsychotic formulation should be granted an exemption from ...
The National Pharmaceutical Pricing Authority's Multidisciplinary Committee of Experts has recommended a five-year exemption for Intas Pharmaceuticals' clozapine extended release capsules from drug pricing norms. This follows confirmation from the Controller General of Patents that the formulation aligns with the company's patent claims. The exemption is based on the drug's new delivery system developed through indigenous research.
Mar 1, 2026
Bristol Myers Squibb's Dividend Strategy in the Wake of GLP-1 Excitement | Intellectia.AI
Piper Sandler has increased its price target on Bristol Myers from $66 to $75, maintaining an Overweight rating. The firm remains optimistic about the company's growth prospects post-Eliquis U.S. exclusivity loss in 2028, citing potential success with milvexian in the LIBREXIA AF study and a strong pipeline of other products.
Mar 1, 2026
Authorities in Bihar have confiscated codeine cough syrups, narcotic injections, and prohibited medications.
Police in Bihar, Chhattisgarh, and Maharashtra have conducted a crackdown on drug diversion, seizing codeine cough syrups, narcotic injections, and banned medicines. This operation is part of a broader anti-narcotics initiative aimed at combating illegal drug distribution in the region.
Mar 1, 2026
Nationwide Debate Erupts Over MTP Kit Seizures: Is It a Legal Abortion Medication or Prohibited?
Drug inspectors in Haryana and other states have intensified efforts to seize Medical Termination of Pregnancy (MTP) kits, igniting a nationwide debate over the legality of the abortion drug. The crackdown raises questions about access to reproductive health services amid ongoing controversies surrounding the MTP kit's regulation.
Mar 1, 2026
Government Analyst Approves Fake Drug Sample in Raipur, Reports DrugsControl Media Services
A counterfeit tablet falsely labeled as a Sun Pharma product has been mistakenly approved as "of Standard Quality" by the Chhattisgarh Government Food and Drug Testing Laboratory in Raipur. This incident highlights significant regulatory failures in drug quality assurance.
Mar 1, 2026
Lonza Group AG Shares: A Subtle Swiss Powerhouse with Significant US Biotech Involvement - Ad-hoc-news.de
Lonza Group AG, a Swiss contract development and manufacturing organization, is gaining attention from investors as a key player in the biotech sector. With a focus on biologics, cell therapies, and complex drug manufacturing, Lonza is positioned to benefit from the growing demand for advanced therapies in the US market. Analysts view it as a stable investment amid the biotech boom.
Mar 1, 2026
Prices for Wegovy and Ozempic to be Reduced in the US Starting in 2027 - indonesiakini
Novo Nordisk will reduce the US list prices of its weight-loss and diabetes drugs, including Wegovy and Ozempic, by up to 50% starting January 1, 2027. This move aims to enhance access for over 100 million Americans with obesity and 35 million with type 2 diabetes, making treatments more competitive against Eli Lilly’s Zepbound.
Mar 1, 2026
Bristol Myers Squibb: An Attractive Investment with Strong Dividends | Intellectia.AI
Piper Sandler has increased its price target on Bristol Myers from $66 to $75, maintaining an Overweight rating. The firm remains optimistic about the company's growth prospects post-Eliquis U.S. exclusivity loss in 2028, citing potential success with milvexian in the LIBREXIA AF study and a strong pipeline of other products.
Mar 1, 2026
A study suggests that medications such as Ozempic could offer unexpected advantages. - NY Post
New research suggests GLP-1 weight loss drugs, such as Ozempic, may effectively treat chronic migraines, potentially outperforming Topamax (topiramate). A study found those on GLP-1s were 10% less likely to visit the ER for migraines and 14% less likely to be hospitalized. While promising, further studies are needed to confirm these findings.
Mar 1, 2026
Novo Nordisk Sets a New Strategic Direction in Response to Market Changes - Ad-hoc-news.de
Novo Nordisk has announced a 50% price cut for its weight-loss drug Wegovy and diabetes medications Ozempic and Rybelsus, effective 2027. The company also entered a $2.1 billion partnership with Vivtex Corporation to develop oral biological medicines. However, it faced a setback with CagriSema, which showed less weight loss than Eli Lilly's Zepbound in trials, causing a 16% drop in shares.
Mar 1, 2026
Liquidia (LQDA) Sees 7.7% Decline Following Introduction of Competing Medication and Patent Concerns - What Lies Ahead
In February 2026, United Therapeutics launched TreSMI, an inhaled treprostinil aimed at reducing coughing, while Liquidia awaits a court ruling on the pivotal ’327 patent litigation. This uncertainty could impact Liquidia's PRINT-enabled treprostinil platform and its competitive position in pulmonary hypertension, as it prepares to report its 2025 results amidst these challenges.
Mar 1, 2026
Liquidia (LQDA) Experiences 7.7% Decline Following Introduction of Competing Medication and Patent Concerns
United Therapeutics has launched TreSMI, a new inhaled treprostinil aimed at reducing coughing, while Liquidia awaits a court decision on the pivotal ’327 patent litigation that could impact its competitive position in pulmonary hypertension. The outcome of this litigation and the introduction of TreSMI may significantly influence Liquidia's investment narrative and market performance.
